5 › 5.1 › 5.1.2
5.1.2 Other laboratory tests
Pages 24 · open in PDF
Recommendations in this section
- Class ILevel CIn patients with suspected HF, the following laboratory tests are recommended when screening for comorbidities: full blood count, kidney function (eGFR and UACR), electrolytes, liver function, thyroid function, HbA1c, lipids, and iron status (TSAT and ferritin).
- Class ILevel CNatriuretic peptide measurement is recommended in patients with suspected HF (interpreted in relation to patient age, obesity, and other factors known to affect natriuretic peptide level).
- Class ILevel CA 12-lead ECG is recommended in patients with suspected HF.
- Class ILevel CChest radiography (X-ray) is recommended in patients with suspected HF.
- Class ILevel CTransthoracic echocardiogram is recommended in patients with suspected HF to confirm the diagnosis, differentiate between HF phenotypes and aid in identifying the underlying aetiology of HF.
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 24 · PDF
required in the assessment of kidney function.164 UACR is independent of glomerular filtration rate (GFR), and severe albuminuria (grade A3) may be present despite GFR ≥90 mL/min/ 1.73 m2. UACR has strong independent prognostic value for patients with HF.165,166 Albuminuria is a potentially treatable and reversible disorder, amenable to medications also used in HF, including ACE-Is/ARNIs/ARBs, MRAs, and SGLT2-Is.167
Table 9 Causes for increase or decrease in natriuretic peptide levels Causes for increased natriuretic peptide levels Acute coronary syndrome Advanced agea Atrial fibrillation Cardiac contusion Critical illness Female sex Kidney dysfunction
LV hypertrophy Myocarditis
In patients with suspected HF, the following laboratory tests are recommended when
screening for comorbidities: full blood count,
kidney function (eGFR and UACR), electrolytes, liver function, thyroid function, HbA1c, lipids,
Pulmonary embolism Pulmonary hypertension
and iron status (TSAT and ferritin).168
Natriuretic peptide measurement is (interpreted in relation to patient age, obesity, and other factors known to affect natriuretic
Severe endocrine dysfunction Severe infections (including pneumonia and sepsis)
A 12-lead ECG is recommended in patients with
Severe metabolic acidosis and diabetic ketoacidosis
Chest radiography (X-ray) is recommended in
patients with suspected HF.
in patients with suspected HF to confirm the
African ancestry ARNI /ACE-I/ARB
diagnosis, differentiate between HF phenotypes and aid in identifying the underlying aetiology of
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; LV, left ventricular; MRA, mineralocorticoid receptor antagonist; RV, right ventricular; SGLT2-I, sodium–glucose co-transporter 2 inhibitor. a See Figure 4. b ARNI may raise BNP levels.
5.1.2. Other laboratory tests Basic investigations, such as serum urea and electrolytes, creatinine, full blood count, glycated haemoglobin, lipids, iron status [transferrin saturation (TSAT) and ferritin], liver and thyroid function tests, are recommended to assess for and evaluate comorbidities, to provide prognostic information, and to guide potential therapy. Urine albumin-to-creatinine ratio (UACR) has been added to the initial baseline investigations, because the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines advise that both estimated glomerular filtration rate (eGFR) and UACR (graded A1, <30 mg/g; A2, 30–300 mg/g; A3, >300 mg/g) are
ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HF, heart failure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TSAT, transferrin saturation; UACR, urine albumin-to-creatinine ratio. a Class of recommendation. b Level of evidence. c See Figure 4 for age-adjusted cut-offs for NT-proBNP levels, and Table 9 for factors affecting natriuretic peptide levels.
5.2. Heart failure phenotypes based on left ventricular ejection fraction Echocardiography provides evaluations of both systolic and diastolic function and valvular function and enables the distinction between HF (stage C) phenotypes based on LVEF.
5.2.1. Heart failure with reduced ejection fraction The diagnosis of HFrEF requires the following criteria: (i) Presence of current or prior symptoms and/or signs of HF (Table 7) (ii) LVEF <50%. Elevated natriuretic peptides strongly support the diagnosis of HFrEF in the presence of symptoms, and may aid in the
Transthoracic echocardiogram is recommended
Causes for decreased natriuretic peptide levels
peptide levelc).146–148,151–153,169
recommended in patients with suspected HF
Recommendation Table 3 — Recommendations for diagnostic investigations in all patients with suspected heart failure (see Evidence Tables 17–19)